Holen Sie sich die Stockscreener-App
315.78
2.30%
7.10
Handel nachbörslich:
320.00
4.22
+1.34%
Insulet Corporation Aktie (PODD) Neueste Nachrichten
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - simplywall.st
Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Investors Can Find Comfort In Insulet's (NASDAQ:PODD) Earnings Quality - 富途牛牛
Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha
Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Institutional & Community Trade Idea Sharing Platform - 선데이타임즈
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance
Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - Nasdaq
Insulet Corporation Reports Strong Q2 2025 Growth - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet: Q2 Earnings Snapshot - Connecticut Post
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
Insulet Corp. stock outperforms competitors on strong trading day - MSN
Insulet Corp. Q2 Profit Decreases, But Beats Estimates - Nasdaq
Canaccord Genuity raises Insulet stock price target to $353 on strong growth - Investing.com Nigeria
Insulet Corporation (PODD) PT Raised to $353 at Canaccord Genuity - StreetInsider
Insulet Ups The Pace Thanks To Demand For Its Wearable Pump - Finimize
Insulet’s Wearable Pumps Propel Earnings Past Wall Street Goals - Finimize
Leerink Partners Raises Price Target on Insulet to $339 From $333 - MarketScreener
Wells Fargo Adjusts Price Target on Insulet to $350 From $330, Maintains Overweight Rating - MarketScreener
Insulet (NASDAQ:PODD) Beats Expectations in Strong Q2, Stock Soars - Yahoo Finance
Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock - Yahoo Finance
Jefferies raises Insulet stock price target to $375 on strong Q2 results - Investing.com Nigeria
0.38%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):